The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize
Industry Leaders Back At The Wheel Are Driving Health Care Transformation
Executive Summary
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.
You may also be interested in...
Minute Insight: Viz.ai Raises $100M To Expand AI-Based Platform To Detect Diseases, Coordinate Care In Hospitals
The latest funding round, led by Tiger Global Management and Insight Partners, values the company at $1.2bn.
Deepak Nath Leaves Siemens To Become Smith & Nephew's New CEO
Deepak Nath will take over as Smith & Nephew’s new CEO on 1 April, joining the orthopedics and wound care company after four years as president of Siemens Healthineers’ diagnostics business. Smith & Nephew’s current CEO Roland Diggelmann is stepping down by mutual agreement.
JPM 2022: Abbott, iRhythm, Novocure, Zimmer Biomet
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.